Kontrol Provides Corporate Update
Kontrol Energy Corp. (OTCQB:KNRLF) has advanced to the commercialization phase of its BioCloud analyzer following successful pre-commercialization testing. The company anticipates launching BioCloud, designed for detecting airborne viruses in populated spaces, by November 2020. Kontrol is engaging with government entities for funding and establishing a supply chain capable of producing up to 20,000 units monthly. With a strengthened balance sheet from $1 Million in cash raised through share options, the company is positioned for growth in the health technology market.
- Progression to commercialization phase for BioCloud analyzer.
- Expected availability of BioCloud units by November 2020.
- Strengthened balance sheet with $1 Million raised from share options.
- Interest from potential customers and distribution partners.
- No claims of revenue made despite ongoing commercialization efforts.
- Risks associated with technology effectiveness in detecting viruses.
Moving Forward with Commercialization of BioCloud
TORONTO, ON / ACCESSWIRE / September 23, 2020 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) ("Kontrol" or "Company") is pleased to provide a corporate update.
"Our team at Kontrol has been very busy since the completion of pre-commercialization testing through the independent labs," says Paul Ghezzi, CEO of Kontrol. "We have now moved to the commercialization phase for the Kontrol BioCloud® analyzer ("BioCloud analyzer" or "BioCloud") which includes further lab testing to establish the lower detection limits. In addition, we are pleased to share that BioCloud is receiving interest from potential customers and distribution partners and we are selecting key suppliers for commercialization. We are in discussions with provincial and federal government entities regarding contributions to commercialization funding and potential future procurement. Our internal goal is to have BioCloud units commercially available in November 2020."
Commercialization of BioCloud
As part of BioCloud's commercialization plans, Kontrol will provide lower detection limits and operating specifications for the analyzer. Initial expectations, based on lab testing completed to date, is that BioCloud will be effective in small to medium space settings with 3 or more people, and therefore would be suitable for applications in many environments such as classrooms, offices, airplanes, trains, buses, long-term care facilities and hospitals.
Like all electrical products, BioCloud is required to operate with a CSA approval in Canada. The Company is in the process of seeking CSA approvals as part of commercialization. CSA is a leader in Standards Development and in Testing, Inspection and Certification around the world including Canada, the U.S., Europe and Asia. The CSA registered mark shows that a product has been independently tested and certified to meet recognized standards for safety or performance. The Company has a long history of success in achieving CSA approvals in our established continuous emissions business.
Operating Subsidiaries, Trademarks and Patents
Kontrol BioCloud Inc., which was recently incorporated, is a wholly owned subsidiary of Kontrol, and will be the primary sales and marketing entity for BioCloud. CEM Specialties Inc. ("CEMSI"), also a wholly owned operating subsidiary of Kontrol, will be the primary research, development, and integration entity for BioCloud.
Kontrol has commenced the trademark of the term Safe Space Technology and has initiated the patent registration for its intellectual property related to BioCloud.
Securing Supply Chain
Kontrol has selected a number of suppliers that will form part of BioCloud supply chain, and we will be announcing those names in the coming weeks, following the issuance of applicable purchase orders.
"While we are not making any claims about revenue at this time, we are building our global supply chain with the goal of being able to supply the market with up to 20,000 units per month," says Gary Saunders VP of Kontrol. "We plan to have this substantially completed over the coming weeks."
Strengthened Balance Sheet and Discussions for Additional Government Funding
As of September 22, 2020, the Company has received approximately
About Kontrol BioCloud
BioCloud is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality continuously. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud has been designed for spaces where individuals gather including classrooms, retirement homes, hospitals, mass transportation and others. It can be an important technology which supports the entire system of individual testing and contact tracing.
The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus).
About Kontrol Energy
Kontrol Energy Corp. (CSE:KNR) (OTCQB:KNRLF) (FSE:1K8) is a leader in the energy efficiency sector through IoT, Cloud and SaaS technology. With a disciplined mergers and acquisition strategy, combined with organic growth, Kontrol Energy Corp. provides market-based energy solutions to our customers designed to reduce their overall cost of energy while providing a corresponding reduction in greenhouse gas (GHG) emissions.
Kontrol Energy is one of Canada's fastest growing companies in 2018 and 2019 as ranked by Canadian Business and Maclean's.
|
|
Additional information about Kontrol Energy Corp. can be found on its website at www.kontrolenergy.com and by reviewing its profile on SEDAR at www.sedar.com.
 |  |  |
For further information, contact:
Paul Ghezzi, Chief Executive Officer
paul@kontrolenergy.com or admin@kontrolenergy.com
Kontrol Energy Corp.,
180 Jardin Drive, Unit 9, Vaughan, ON L4K 1X8
Tel: 905.766.0400, Toll free: 1.844.566.8123
Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains "forward-looking information" within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as "may", "will", "expect", "likely", "should", "would", "plan", "anticipate", "intend", "potential", "proposed", "estimate", "believe" or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions "may" or "will" happen, or by discussions of strategy.
Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated.
However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company's product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. In particular, successful development and commercialization of the Kontrol BioCloud Analyzer are subject to the risk that the Kontrol BioCloud Analyzer may not prove to be successful in detecting the virus that causes COVID-19 effectively or at all, uncertainty of timing or availability of any regulatory approvals and Kontrol's lack of track record in developing products for medical applications.
Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.
SOURCE: Kontrol Energy Corp.
View source version on accesswire.com:
https://www.accesswire.com/607392/Kontrol-Provides-Corporate-Update
FAQ
What is Kontrol Energy's plan for the BioCloud analyzer?
How much cash has Kontrol Energy raised recently?
What markets is Kontrol targeting with BioCloud?
Is Kontrol Energy receiving government support for BioCloud?
What is the expected production capacity for BioCloud units?
